Tuesday, October 7, 2025

Latest

Mind Medicine: Canaccord Maintains Ratings Following Financial Results

On Friday, November 13th, Mind Medicine (NEO: MMED) reported their third quarter 2020 financial results. Tania Gonsalves, Canaccord Genuity’s biotechnology analyst, has a C$2 price target and a speculative buy rating.

Gonsalves comments, “As a clinical-stage biotechnology company, quarterly financials are not a materially impactful event, apart from unexpected variations in forecast cash burn.”

Operating expenses came in at $6.9 million, $900k above their $5.8 million estimate. The reason costs came in higher was due to R&D expenses, which were $5.3 million compared to the forecast of $3.9 million. General and administrative expenses however came below her estimate of $2 million. The company reported a net loss of $8.7 million, above Canaccord’s estimate of $7.2 million.

Gonsalves says that they are extending their estimate of when Phase 1b trial of their 118-MC addiction program to the fourth quarter of 2020 and now assuming phase 2 trial begins in 2021. She justifies this by stating, “there was no mention of completion in the financials.”

Onto Mind Medicine’s LSD microdose program, Gonsalves says that they continue to model for the trial to start in Q4/20 but adds, “it could be delayed to Q1/20. Phase 2 trials are expected to be complete by the end of 2022.”

With Mind Medicine expenses being over estimates, Tania has now increased her R&D expenses by $1.5 million in the fourth quarter and $1 million in 2021, “to account for Phase 1 trials slated to begin before year-end.”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Fortune Bay: The Potential Billion Dollar Project

Japan Gold Enters New Chapter as Barrick Alliance Concludes – John Proust

Barrick Mining’s “Company Defining [Gold] Discovery”

Recommended

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Related News

Hexo: Canaccord Cuts Price Target In Half To $1.00

On December 14th, Hexo Corp (TSX: HEXO) reported its fiscal first quarter 2022 results. The...

Saturday, December 18, 2021, 01:23:00 PM

Enthusiast Gaming: Canaccord Raises Price Target To $8.75

Last week, Enthusiast Gaming (TSX: EGLX) announced that they closed a $58.7 million bought deal....

Sunday, February 14, 2021, 01:35:00 PM

Canaccord Smacks Canopy Growth With $12 Price Target

On November 5th, Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) reported their fiscal second quarter...

Monday, November 8, 2021, 10:14:00 AM

Beacon Expects NG Energy’s Sinu-9 Approval To Arrive Soon

On August 25, NG Energy (TSXV: GASX) reported its second quarter financial results. Although there...

Monday, August 30, 2021, 11:31:00 AM

Lundin Gold Sees BMO Reiterate $14 Price Target After Production Beat

On January 10th, Lundin Gold Inc. (TSX: LUG) announced its 2021 full-year production results. The...

Saturday, January 15, 2022, 03:21:00 PM